NEW YORK (GenomeWeb News) – BioNanomatrix has received a Phase II grant in the amount of nearly $2.1 million from the National Human Genome Research Institute to support further development of the firm's single-molecule nanoscale whole-genome analyzer.
The 30-month Small Business Innovation Research award was made under the BioEngineering Nanotechnology Initiative, which is intended to support the development of nanotechnologies for biomedicine applications. The newest grant follows completion of a similar Phase I grant for initial development of the technology.
"BioNanomatrix's nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level with very high resolution, yielding a great deal of genomic information that is not currently accessible," said BioNanomatrix President and CEO Michael Boyce-Jacino in a statement. "We believe our technology has the potential to increase the utility of whole-genome imaging and analysis for a wide range of research and diagnostic applications, and we are delighted at NHGRI's renewed vote of confidence in the potential of our program."
Philadelphia-based BioNanomatrix also is working with Complete Genomics on a DNA sequencer that they hope will achieve the "$100 genome." The firms received $8.8 million in funding from the National Institute of Standards and Technology in October 2007 to support efforts to combine BioNanomatrix’s nanofluidic DNA imaging device and Complete Genomics’ sequencing chemistry.